Please login to the form below
psoriatic arthritis
This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.
BMS psoriasis drug hits the mark in phase II
which brought in $1.3bn in sales last year in psoriasis and psoriatic arthritis. ... Pfizer’s Xeljanz (tofacitinib) has been approved for psoriatic arthritis but was turned down by the FDA for psoriasis in 2015.
Latest news
-
Gilead, Galapagos JAK inhibitor clears phase II test
In the TORTUGA trial, filgotinib met its clinical objective of reducing disease activity scores compared to placebo in patients with AS, a severe form of arthritis affecting the spine, with more ... Like filgotinib, upadacitinib is also being tested in a
-
Boehringer beefs up biologics capacity with €230m investment
That includes its portfolio of biosimilar drugs, as well as novel candidates such as AbbVie-partnered interleukin-23 inhibitor risankizumab – in phase III trials in psoriasis and psoriatic arthritis – and
-
Boehringer beefs up biologics capacity with €230m investment
That includes its portfolio of biosimilar drugs, as well as novel candidates such as AbbVie-partnered interleukin-23 inhibitor risankizumab – in phase III trials in psoriasis and psoriatic arthritis – and
-
AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib. Patients with RA reported an improvement in mobility pain on the JAK1 inhibitor. ... Meanwhile, following the same path as Xeljanz, upadacitinib is also being tested in a string of
-
Pfizer’s Xeljanz picks up a third indication in IBD
placebo. Xeljanz is already doing well in the arthritis disease area - after picking up US approvals in rheumatoid arthritis and psoriatic arthritis - where the drug is the first and only JAK
More from news
Approximately 13 fully matching, plus 111 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic
-
Deal Watch December 2016
510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small
-
Taking a strategic approach
Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of
-
Pharma deals during July 2014
Cimzia, a pegylated antibody fragment that blocks tumour necrosis factor alpha, is currently indicated for several disorders including Crohn's disease, rheumatoid arthritis and psoriatic arthritis.
-
An eye towards the biobetter in South Korea
Emerging area. Marketed in 2007. RA = rheumatoid arthritis; AS = ankylosing spondylitis; CD = Crohn's disease; PA = psoriatic arthritis; PS = psoriasis;.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Millefeuille
Millefeuille. This story of hope charts Élodie’ s physical and mental struggles with psoriasis and psoriatic arthritis. ... For more information please visit http://bedrock-health.com/millefeuille/. Millefeuille. This story of hope charts Élodie’ s
-
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis. Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this ... In this month’ s column we discuss how
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Manager
-
Negotiable
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Systematic Review Lead- London
-
Negotiable
- Account Director or Senior Account Director
-
Salary TBC
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Senior Medical Writer
-
Salary is DOE
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
Subscribe to our email news alerts
PMHub
Complete Medical Communications (CMC)
CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...
Latest intelligence
- The gene therapy revolution
- Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
Quick links
Infographics
